Sanofi India (500674) Q4 2024 earnings summary

Executive summary

• Board approved audited standalone and consolidated results for the year ended December 31, 2024, with an unmodified audit opinion from statutory auditors.

• Demerger of Consumer Healthcare business into Sanofi Consumer Healthcare India Limited effective June 1, 2024; SCHIL ceased to be a subsidiary from that date.

• Final dividend of ₹117 per equity share recommended for FY2024, subject to shareholder approval.

Financial highlights

• Standalone revenue from operations for FY2024 was ₹20,132 million, up slightly from ₹19,961 million in FY2023.

• Standalone profit from continuing operations for FY2024 was ₹3,137 million, down from ₹3,646 million in FY2023.

• Standalone total comprehensive income for FY2024 was ₹4,207 million, compared to ₹6,019 million in FY2023.

• Q4-2024 standalone profit from operations was ₹108 crore, up 21% year-over-year; net sales grew 8% year-over-year.

• Consolidated profit for FY2024 was ₹4,133 million, down from ₹6,029 million in FY2023.

Outlook and guidance

• Focus remains on expanding diabetes portfolio, with double-digit growth for Toujeo and successful launch of Soliqua.

• Partnerships in CNS and cardiovascular segments are progressing as planned, supporting future growth.

• Continued emphasis on operating efficiency and innovation under the 'India for India' strategy.